Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4046/trd.2014.77.3.105 http://scihub22266oqcxt.onion/10.4046/trd.2014.77.3.105 25309604!4192307!25309604     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Tuberc+Respir+Dis+(Seoul) 2014 ; 77 (3): 105-10 Nephropedia Template TP {{tp|p=25309604|t=2014. Respiratory review of 2014: pulmonary thromboembolism |pdf=|usr=}}{{25309604}} gab.com Text Respiratory review of 2014: pulmonary thromboembolism JO: Tuberc Respir Dis (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=25309604 #FOAvip Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is an important cause of morbidity and mortality. The aim of this review is to summarize the findings from clinically important publications over the last year in the area of VTE. In this review, we discuss 11 randomized controlled trials published from March 2013 to April 2014. The COAG and the EU-PACT trials indicate that pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or marginal usefulness in the Caucasian population. Recent clinical trials with novel oral anticoagulants (NOACs) have demonstrated that the efficacy and safety of rivaroxaban, apixaban, edoxaban, and dabigatran are not inferior to those of conventional anticoagulants for the treatment of VTE. The PEITHO and ULTIMA trials suggested that rescue thrombolysis or catheter-directed thrombolysis may maximize the clinical benefits and minimize the bleeding risk. Lastly, riociguat has a proven efficacy in treating chronic thromboembolic pulmonary hypertension. In the future, NOACs, riociguat, and catheter-directed thrombolysis have the potential to revolutionize the management of patients with VTE. Twit Text FOAVip Respiratory review of 2014: pulmonary thromboembolism ????Tuberc Respir Dis (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=25309604 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25309604 #FOAvip English Wikipedia <ref>{{Cite pmid|25309604}}</ref> Respiratory review of 2014: pulmonary thromboembolism #MMPMID25309604 Lee JS Tuberc Respir Dis (Seoul) 2014[Sep]; 77 (3): 105-10 PMID25309604show ga Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is an important cause of morbidity and mortality. The aim of this review is to summarize the findings from clinically important publications over the last year in the area of VTE. In this review, we discuss 11 randomized controlled trials published from March 2013 to April 2014. The COAG and the EU-PACT trials indicate that pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or marginal usefulness in the Caucasian population. Recent clinical trials with novel oral anticoagulants (NOACs) have demonstrated that the efficacy and safety of rivaroxaban, apixaban, edoxaban, and dabigatran are not inferior to those of conventional anticoagulants for the treatment of VTE. The PEITHO and ULTIMA trials suggested that rescue thrombolysis or catheter-directed thrombolysis may maximize the clinical benefits and minimize the bleeding risk. Lastly, riociguat has a proven efficacy in treating chronic thromboembolic pulmonary hypertension. In the future, NOACs, riociguat, and catheter-directed thrombolysis have the potential to revolutionize the management of patients with VTE. äRespiratory review of 2014: pulmonary thromboembolism (epmc).pdf DeepDyve Pubget Overpricing